Clinical Trial: Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)

U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07811882) titled 'Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)' on Sept. 04.

Brief Summary: This is Cohort B1 of the Platform study (NCT05750628) to evaluate the efficacy and safety of INE963 + Cipargamin in participants with uncomplicated Plasmodium falciparum malaria.

Study Start Date: Oct. 10, 2025

Study Type: INTERVENTIONAL

Condition: Uncomplicated Plasmodium Falciparum Malaria

Intervention: DRUG: KAE609 (Cipargamin)

oral KAE609 (Cipargamin)

DRUG: SoC (Coartem)

SoC (Coartem)

DRUG: INE963

oral INE963

Recruitment Status: COMPLETED...